Food News and Research

RSS

Reducing sodium in common foods could prevent heart disease and stroke

Lowering sodium in packaged and prepared foods could significantly improve cardiovascular health and prevent many cases of heart disease, stroke and deaths in the general population in France and the U.K., according to two new research studies published today in Hypertension, an American Heart Association journal.

26 Jan 2026

Olive oil type matters for cognition and gut health in older adults

Higher intake of virgin and total olive oil was associated with modest but significant improvements in cognitive performance over two years in older adults with metabolic syndrome. These associations were partly linked to gut microbiota composition, with specific taxa such as Adlercreutzia contributing a small mediating effect.

26 Jan 2026

Tiny plastic particles may interfere with brain processes implicated in Parkinson’s disease

Micro- and nanoplastics are increasingly detected in human tissues, including the brain, and experimental evidence suggests they can interact with biological pathways central to Parkinson’s disease pathology. This review synthesises mechanistic data indicating that plastic particles may influence protein aggregation, neuroinflammation, mitochondrial dysfunction, and the gut–brain axis, while emphasising the need for prospective human studies.

26 Jan 2026

Three daily servings of full-fat dairy do not worsen weight or blood markers

This randomized 12-week trial examined whether adding three daily servings of full-fat dairy to diets aligned with Canada’s Food Guide affects body weight, cardiometabolic markers, and nutrient intake in adults with overweight or obesity. Full-fat dairy intake did not adversely affect weight, body composition, or metabolic health and increased calcium and protein intake, supporting dietary compatibility rather than therapeutic benefit.

26 Jan 2026

Secondary-treated wastewater still transfers antibiotic resistance to fresh produce

A study reveals tertiary-treated wastewater significantly reduces antimicrobial resistance risks in lettuce irrigation compared to secondary-treated water.

26 Jan 2026

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.

25 Jan 2026

Experimental study reveals advanced episodic memory replay in rats

In a new study Indiana University researchers observed episodic memory in rats to a degree never documented before, suggesting that rats can serve as a model for complex cognitive processes often considered exclusively human.

24 Jan 2026

Blood-based epigenetic signatures enable early risk assessment in prediabetes

Prediabetes is an extremely heterogeneous metabolic disorder. Scientists from several partner institutes of the German Center for Diabetes Research (DZD) have now used artificial intelligence (AI) to identify epigenetic markers that indicate an elevated risk of complications.

24 Jan 2026

Short-term oatmeal diet improves cholesterol and metabolic health markers

A short-term oat-based diet appears to be surprisingly effective at reducing the cholesterol level. This is indicated by a trial by the University of Bonn, which has now been published in the journal Nature Communications.

23 Jan 2026

AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has recently received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA), intended for the treatment of Parkinson's Disease.

23 Jan 2026

Why medication abortion is the top target for anti-abortion groups in 2026

This week would have marked the 53rd anniversary of Roe v. Wade, the 1973 Supreme Court decision that legalized abortion nationwide — that is, until 2022, when the court overturned it. Since then, abortion has been banned in 13 states and severely limited in 10 others.

23 Jan 2026

Genetic study links vitamin B1 metabolism to gut motility and IBS risk

Research links thiamine metabolism to gut motility, identifying genetic markers that could lead to new therapies for IBS and related digestive disorders.

23 Jan 2026

FDA warns consumers about fake cancer cures sold online

Beware of products claiming to cure cancer on websites or social media platforms, such as Facebook and Instagram. According to Nicole Kornspan, M.P.H., a consumer safety officer at the U.S. Food and Drug Administration (FDA), they're rampant these days.

22 Jan 2026

Menopausal hormone therapy linked to greater weight loss with tirzepatide

A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity.

22 Jan 2026

When you eat matters: early time-restricted eating improves metabolic health

Time-restricted eating improves several metabolic outcomes compared with usual diets, with benefits observed for body weight, adiposity, blood pressure, insulin, glucose, and triglycerides. Early eating windows consistently outperform late eating, while the optimal duration of food intake remains uncertain.

22 Jan 2026

Survey shows growing public familiarity with RSV vaccines and antibody injections

Amid a surprisingly severe flu season and a Covid-19 resurgence, those highly contagious respiratory illnesses are drawing the largest share of media coverage and public attention.

21 Jan 2026

GLP-1 weight-loss drugs show early promise for treating addiction

This systematic review evaluates preclinical and clinical evidence on glucagon-like peptide-1 receptor agonists as potential treatments for substance use disorders. Findings show consistent reductions in drug- and alcohol-seeking behaviors in animal models, while human evidence remains limited, heterogeneous, and preliminary.

21 Jan 2026